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1. Introduction
Opioids and cannabinoids are a group of endogenous and exo-
genous compounds that function through activation of their 
respective receptors (opioid receptors: µ, δ, and κ, cannabinoid 
receptors: CB1 and CB2) [1,2]. Besides their analgesia and psy-
choactive functions, opioid/cannabinoids systems have received 
remarkable attention since they can modulate the immune 
response, which affects immune-associated disease progression 
[3,4]. Modulation of the immune response by opioids/cannabi-
noids may be achieved through induction of apoptosis, suppres-
sion of cell proliferation, inhibition of pro-inflammatory and 
inflammatory cytokines/chemokines production, increase in anti- 
inflammatory cytokines, and induction of regulatory T cells [5,6]. In 
vitro and in vivo studies as well as findings in humans indicate that 
these systems positively or negatively affect viral replication and 
virus-mediated pathology. Depending on the type of virus, opioid/ 
cannabinoid systems have different favorable and unfavorable 
effects on the outcome of the viral infection [7,8]. In viral infections 
where the host inflammatory response is pathogenic (known as 
immunopathogenic), activation of opioid/cannabinoid receptors 
is beneficial for control of immunopathology [7–9].
There are several pieces of evidence about the specific involve-
ment of opioids/cannabinoids systems in respiratory viral- 
associated immunopathology and in modulating inflammation 
[7,8]. The data from our studies, for the first time, provided evi-
dence that opioids/cannabinoids systems play an important role 
in respiratory syncytial virus (RSV) disease severity, which is the 
most common inflammatory disease in early childhood [10–12]. 
Immunopathogenesis of the RSV is one of the important aspects, 
causing severe illness in some cases since the infiltration of 
immune cells into the lung tissue and obstruction of the airways 
can lead to shortness of breath, bronchiolitis, pneumonia, and 
even death [13]. Using human studies and experimental models, 
we showed that opioids/cannabinoids signaling has a potentially 
beneficial role in the outcome of RSV disease. In these studies, the 
opioids/cannabinoids receptors blockade is associated with 
enhanced immunopathology, such as immune cell influx and 
increased cytokines/chemokines production, along with RSV- 
induced lung pathology and weight loss. However, activation of 
these receptors using agonists decreased immune cell influx and 
cytokine/chemokine production, and alleviated lung pathology. 
Results suggest that the opioid system impairs or modulates 
immune responses induced by the influenza virus that might be 
beneficial for controlling viral immunopathogenesis [14,15]. 
Several studies also indicated that the lack of cannabinoid recep-
tors could increase inflammation and tissue damage following 
influenza virus infection and their activation can impair immune 
responses induced by the virus [16–18]. Such data and effects of 
opioids/cannabinoids systems on other viruses such as HIV, HCV, 
HSV, and others [7,8] indicated that these systems may serve as 
therapeutic targets through the alleviation of virus-induced 
inflammation. How could we translate these data into the new 
coronavirus?
2. Opioids/cannabinoids systems and COVID-19
COVID-19 is a viral respiratory disease caused by a new 
coronavirus called severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2) [19]. The emergence of SARS-CoV 
-2 in China at the end of 2019 has caused a large global 
outbreak that is a major public health problem with inter-
national concern [20]. At the moment, there is little data 
regarding the pathogenesis of SARS-CoV-2 and we only 
have informed guesses regarding the virus behavior. 
However, data from previous coronaviruses such as SARS- 
CoV and MERS-CoV indicated that a dysregulated/exuber-
ant innate immune response is a leading contributor to the 
virus-mediated pathology [21]. Although a strong innate 
immune response is essential to eliminate viral pathogens, 
a prolonged or dysregulated/exuberant manner can 
damage the respiratory tract. It seems that besides under-
lying diseases, older age, and high viral titer, intensive 
inflammation correlates with adverse outcomes of SARS- 
CoV-2 infection [22]. In this regard, sustained inflammation 
(known as cytokine storm) has been observed in the 
majority of severe COVID-19 cases [23]. High concentra-
tions of cytokines such as IL-2, IL-7, IL-10, G-SCF, IP10, 
MCP1, MIP1A, and TNF-α were recorded in plasma of 
CONTACT Alireza Tahamtan dr.tahamtan@goums.ac.ir Infectious Diseases Research Centre, Golestan University of Medical Sciences, Gorgan, Iran; Vahid 
Salimi vsalimi@tums.ac.ir Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 
This article has been republished with minor changes. These changes do not impact the academic content of the article.
EXPERT REVIEW OF RESPIRATORY MEDICINE                                                                                                                  
2020, VOL. 14, NO. 10, 965–967 
https://doi.org/10.1080/17476348.2020.1787836                                                                                                                                                                                        
© 2020 Informa UK Limited, trading as Taylor & Francis Group
critically ill patients infected with SARS-CoV-2, indicating 
that the cytokine storm could be associated with disease 
severity [24]. Importantly, while lymphopenia is a hallmark 
of COVID-19, there are numerous differences in laboratory 
findings between patients admitted to the intensive care 
unit (ICU) and those not admitted to the ICU, including 
higher white blood cell and neutrophil counts [25].
So far, no vaccine has been successfully developed and there 
is no effective treatment of COVID-19. Since intensive inflamma-
tion leads to disease-induced morbidity and mortality, inhibition 
of the hyperinflammatory response is a definitive drug therapy 
objective. Appealing evidence in similar infections and related 
diseases might pave the way toward rapidly COVID-19 growing 
pandemic. As an example, there have been reports regarding 
increasing interest in using IL-6 inhibitors (as a treatment for 
rheumatoid arthritis) to treat patients with severe COVID-19 
infection, including a non-peer-reviewed retrospective Chinese 
experience describing 21 COVID-19 positive patients with severe 
illness who received tocilizumab. It is important to note that 
cytokine inhibitors are available and specific only for a few of the 
cytokines involved in the inflammatory cascade. Certainly, there 
is an urgent need for a substance that can potentially counter 
the effects of the virus and alleviate the symptoms and severity 
of the disease. Could opioids/cannabinoids be an effective treat-
ment for COVID-19?
Infection is regulated by multiple cytokines that they act in 
concert to proceed with inflammatory responses. However, in 
some of viral infection, a storm of cytokines and chemokines 
occurs during infection that should take into account. It seems 
that in the case of severe COVID-19 patients balancing virus 
clearance and immunopathology through immunomodulators 
might be effective. Since opioids/cannabinoids receptors-based 
drugs can modulate immune cell migration and cytokine/che-
mokine secretion, they represent a promising pharmacological 
platform for developing anti-inflammatory therapeutics. 
Therefore in the absence of effective treatments to decrease 
the damage associated with COVID-19 especially in those 
admitted to the ICU and suffer from exaggerated inflammatory 
response, opioids/cannabinoids receptor agonists might poten-
tially open up an effective therapeutic approach in COVID-19 
infection. Notably, the biocompatibility, availability, and cheap-
ness are considerable privileges of opioids/cannabinoids-based 
drugs. More research will be needed to determine which 
opioids/cannabinoids products and mixtures might be effective 
in treating COVID-19 and at what concentrations.
3. Expert opinion
It is interesting to remember that physicians in the late 19th 
century used anodynes of opium tincture as a treatment of 
‘bronchitis’ and other ailments in infants and children, as case 
reports and experience ‘demonstrated the efficacy’ of the 
concoction in controlling coughing and facilitating breathing. 
Also, today some products of cannabinoids are used to mod-
ulate an inflammatory response. This permits us to rediscover 
the past and utilize the present, with hopes of finding the 
missing links in the pathophysiology of COVID-19, and raises 
the issue of opioids/cannabinoids utilization in the context of 
COVID-19. It is suggested that clinical trials could be 
conducted on opioids/cannabinoids products with immuno-
modulatory activity. We hope that, with great efforts, scientific 
support, and sharing of information, the overcoming of 
COVID-19 will come soon.
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